Clinical trials of biosimilars should become more similar

Annals of the Rheumatic Diseases

Volumn 76, Issue 1, 2017, Pages 4-6

  Kay, Jonathan ^a   Isaacs, John D ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BIOSIMILAR AGENT; DRUG ANTIBODY; ETANERCEPT; HD 203; INFLIXIMAB; INFLIXIMAB DYYB; PLACEBO; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL RESEARCH; DRUG APPROVAL; DRUG EFFICACY; DRUG MARKETING; DRUG RESPONSE; DRUG SAFETY; HUMAN; IMMUNOGENICITY; INJECTION SITE REACTION; REVIEW; SIDE EFFECT; RHEUMATOID ARTHRITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOSIMILAR PHARMACEUTICALS; INFLIXIMAB; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84984596871     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-208113     Document Type: Review

References (26)

1. GaBI Online - Generics and Biosimilars Initiative. Biosimilar monoclonal antibody approved in Korea. 2012. http://www.gabionline.net/Biosimilars/News/Biosimilar-monoclonal-antibody-approved-in-Korea (accessed 22 Jun 2016).
2. Dörner T, Strand V, Cornes P, et al. The changing landscape of biosimilars in rheumatology. Ann Rheum Dis 2016; 75: 974-82.
3. European Medicines Agency. Remsima. 2016. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002576/human-med-001682.jsp&mid=WC0b01ac058001d124 (accessed 22 Jun 2016).
4. Celltrion Inc. Approved products: Remsima, the world first biosimilar mAb. 2015. http://www.celltrion.com/en/products/license.do (accessed 22 Jun 2016).
5. GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in South Korea. 2016. http://www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-South-Korea (accessed 22 Jun 2016).
6. European Medicines Agency. Benepali. 2016. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004007/human-med-001944.jsp&mid=WC0b01ac058001d124 (accessed 22 Jun 2016).
7. European Medicines Agency. Flixabi. 2016. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004020/human-med-001980.jsp&mid=WC0b01ac058001d124 (accessed 22 Jun 2016).
8. Bae SC, Kim J, Choe JY, et al. A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study. Ann Rheum Dis 2017; 76: 65-71.
9. Emery P, Vencovsky J, Sylwestrzak A, et al. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 2017; 76: 51-7.
10. Choe JY, Prodanovic N, Niebrzydowski J, et al. A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 2017; 76: 58-64.
11. Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products. 2005. http://www.emea.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003517.pdf (accessed 22 Jun 2016).
12. United States Department of Health & Human Services, Food & Drug Administration. Guidance for industry: Scientific considerations in demonstrating biosimilarity to a reference product, draft guidance. 2012. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf (accessed 22 Jun 2016).
13. Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013; 72: 1613-20.
14. Yoo DH, Racewicz A, Brzezicki J, et al. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. Arthritis Res Ther 2015; 18: 82.
15. Kay J, Smolen JS. Biosimilars to treat inflammatory arthritis: the challenge of proving identity. Ann Rheum Dis 2013; 72: 1589-93.
16. Ng T-H. Choice of delta in equivalence testing. Drug Inf J 2001; 35: 1517-27.
17. Committee for Medicinal Products for Human Use. Guideline on the choice of the non-inferiority margin. 2005. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003636.pdf (accessed 18 Jul 2016).
18. United States Department of Health & Human Services, Food & Drug Administration. Guidance for industry: Statistical approaches to establishing bioequivalence. 2001. http://www.fda.gov/downloads/Drugs/⋯/Guidances/ucm070244.pdf (accessed 18 Jul 2016).
19. Committee for Medicinal Products for Human Use. Assessment report: Benepali. 2015. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment-report/human/004007/WC500200380.pdf (accessed 22 Jun 2016).
20. Emery P, Vencovský J, Kang JW, et al. Confirmation on the immunogenicity assay used in the SB4 phase III study: response to the comments by Meacci et al. Ann Rheum Dis 2016; 75: e40.
21. Committee for Medicinal Products for Human Use. CHMP assessment report: Flixabi. 2016. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment-report/human/004020/WC500208358.pdf (accessed 22 Jun 2016).
22. van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2013; 9: 164-72.
23. United States Department of Health & Human Services, Food & Drug Administration. Guidance for industry: Immunogenicity assessment for therapeutic protein products. 2014. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm338856.pdf (accessed 22 June 2016).
24. Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products. 2014. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2014/10/WC500176768.pdf (accessed 22 Jun 2016).
25. Lee YJ, Shin D, Kim Y, et al. A randomised Phase l pharmacokinetic study comparing SB4 and etanercept reference product (Enbrel®) in healthy subjects. Br J Clin Pharmacol 2016; 82: 64-73.
26. Kim SC, Choi NK, Lee J, et al. Brief report: utilization of the first biosimilar infliximab since its approval in South Korea. Arthritis Rheumatol 2016; 68: 1076-9.